FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 331:393-394 August 11, 1994 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Maintaining a balance between adequate immunosuppression to prevent the rejection of an allograft and excessive immunosuppression, with its attendant risks of opportunistic infections and neoplasia, has always been the quintessential challenge for the transplantation physician. "Save the patient, not the graft" is a reasonable maxim, since renal-transplant recipients, unlike patients receiving other solid-organ grafts, have dialysis available to replace organ function. As Suthanthiran and Strom point out in this issue of the Journal,¹ we have now been learning for over a decade how best to use cyclosporine, which reduces the incidence of acute rejection² and improves graft survival at one . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.